Cynosure, Inc. (NASDAQ: CYNO) Stock Competitors & Peer Comparison

Cynosure, Inc. (NASDAQ: CYNO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYNO stands at 0. In comparison, SIRO has a market cap of 22B. Regarding current trading prices, CYNO is priced at $66.00 on the NASDAQ, while SIRO trades at $109.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYNO currently has a P/E ratio of 105.35, whereas SIRO's P/E ratio is 31.88. In terms of profitability, CYNO's ROE is +0.03%, compared to SIRO's ROE of +0.14%. Regarding short-term risk, CYNO is less volatile compared to SIRO. This indicates lower risk in terms of short-term price fluctuations for CYNO.Check SIRO's competition here

Cynosure, Inc. (NASDAQ: CYNO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYNO stands at 0. In comparison, HIMS has a market cap of 7B. Regarding current trading prices, CYNO is priced at $66.00 on the NASDAQ, while HIMS trades at $31.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYNO currently has a P/E ratio of 105.35, whereas HIMS's P/E ratio is -315.90. In terms of profitability, CYNO's ROE is +0.03%, compared to HIMS's ROE of -0.02%. Regarding short-term risk, CYNO is less volatile compared to HIMS. This indicates lower risk in terms of short-term price fluctuations for CYNO.Check HIMS's competition here

Cynosure, Inc. (NASDAQ: CYNO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYNO stands at 0. In comparison, MMED has a market cap of 5.5B. Regarding current trading prices, CYNO is priced at $66.00 on the NASDAQ, while MMED trades at $19.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYNO currently has a P/E ratio of 105.35, whereas MMED's P/E ratio is -25.29. In terms of profitability, CYNO's ROE is +0.03%, compared to MMED's ROE of -0.14%. Regarding short-term risk, CYNO is less volatile compared to MMED. This indicates lower risk in terms of short-term price fluctuations for CYNO.Check MMED's competition here

Cynosure, Inc. (NASDAQ: CYNO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYNO stands at 0. In comparison, OMCL has a market cap of 1.7B. Regarding current trading prices, CYNO is priced at $66.00 on the NASDAQ, while OMCL trades at $36.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYNO currently has a P/E ratio of 105.35, whereas OMCL's P/E ratio is 19.27. In terms of profitability, CYNO's ROE is +0.03%, compared to OMCL's ROE of +0.03%. Regarding short-term risk, CYNO is less volatile compared to OMCL. This indicates lower risk in terms of short-term price fluctuations for CYNO.Check OMCL's competition here

Cynosure, Inc. (NASDAQ: CYNO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYNO stands at 0. In comparison, DRTS has a market cap of 1.2B. Regarding current trading prices, CYNO is priced at $66.00 on the NASDAQ, while DRTS trades at $13.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYNO currently has a P/E ratio of 105.35, whereas DRTS's P/E ratio is -19.61. In terms of profitability, CYNO's ROE is +0.03%, compared to DRTS's ROE of -0.73%. Regarding short-term risk, CYNO is less volatile compared to DRTS. This indicates lower risk in terms of short-term price fluctuations for CYNO.Check DRTS's competition here

Cynosure, Inc. (NASDAQ: CYNO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYNO stands at 0. In comparison, MLAB has a market cap of 574.4M. Regarding current trading prices, CYNO is priced at $66.00 on the NASDAQ, while MLAB trades at $102.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYNO currently has a P/E ratio of 105.35, whereas MLAB's P/E ratio is 10.36. In terms of profitability, CYNO's ROE is +0.03%, compared to MLAB's ROE of +0.04%. Regarding short-term risk, CYNO is less volatile compared to MLAB. This indicates lower risk in terms of short-term price fluctuations for CYNO.Check MLAB's competition here

Cynosure, Inc. (NASDAQ: CYNO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYNO stands at 0. In comparison, LAB has a market cap of 313.2M. Regarding current trading prices, CYNO is priced at $66.00 on the NASDAQ, while LAB trades at $0.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYNO currently has a P/E ratio of 105.35, whereas LAB's P/E ratio is -11.43. In terms of profitability, CYNO's ROE is +0.03%, compared to LAB's ROE of -0.18%. Regarding short-term risk, CYNO is less volatile compared to LAB. This indicates lower risk in terms of short-term price fluctuations for CYNO.Check LAB's competition here

Cynosure, Inc. (NASDAQ: CYNO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYNO stands at 0. In comparison, STXS has a market cap of 139M. Regarding current trading prices, CYNO is priced at $66.00 on the NASDAQ, while STXS trades at $1.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYNO currently has a P/E ratio of 105.35, whereas STXS's P/E ratio is -8.35. In terms of profitability, CYNO's ROE is +0.03%, compared to STXS's ROE of -1.53%. Regarding short-term risk, CYNO is less volatile compared to STXS. This indicates lower risk in terms of short-term price fluctuations for CYNO.Check STXS's competition here

Cynosure, Inc. (NASDAQ: CYNO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYNO stands at 0. In comparison, FONR has a market cap of 117.8M. Regarding current trading prices, CYNO is priced at $66.00 on the NASDAQ, while FONR trades at $19.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYNO currently has a P/E ratio of 105.35, whereas FONR's P/E ratio is 19.09. In terms of profitability, CYNO's ROE is +0.03%, compared to FONR's ROE of +0.04%. Regarding short-term risk, CYNO is more volatile compared to FONR. This indicates higher risk in terms of short-term price fluctuations for CYNO.Check FONR's competition here

Cynosure, Inc. (NASDAQ: CYNO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYNO stands at 0. In comparison, LNSR has a market cap of 74.2M. Regarding current trading prices, CYNO is priced at $66.00 on the NASDAQ, while LNSR trades at $6.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYNO currently has a P/E ratio of 105.35, whereas LNSR's P/E ratio is 6.16. In terms of profitability, CYNO's ROE is +0.03%, compared to LNSR's ROE of -5.15%. Regarding short-term risk, CYNO is less volatile compared to LNSR. This indicates lower risk in terms of short-term price fluctuations for CYNO.Check LNSR's competition here

Cynosure, Inc. (NASDAQ: CYNO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYNO stands at 0. In comparison, KDLY has a market cap of 68.1M. Regarding current trading prices, CYNO is priced at $66.00 on the NASDAQ, while KDLY trades at $11.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYNO currently has a P/E ratio of 105.35, whereas KDLY's P/E ratio is -15.48. In terms of profitability, CYNO's ROE is +0.03%, compared to KDLY's ROE of -0.85%. Regarding short-term risk, CYNO is less volatile compared to KDLY. This indicates lower risk in terms of short-term price fluctuations for CYNO.Check KDLY's competition here

Cynosure, Inc. (NASDAQ: CYNO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYNO stands at 0. In comparison, NEUE has a market cap of 60.9M. Regarding current trading prices, CYNO is priced at $66.00 on the NASDAQ, while NEUE trades at $6.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYNO currently has a P/E ratio of 105.35, whereas NEUE's P/E ratio is -0.38. In terms of profitability, CYNO's ROE is +0.03%, compared to NEUE's ROE of +0.05%. Regarding short-term risk, CYNO is less volatile compared to NEUE. This indicates lower risk in terms of short-term price fluctuations for CYNO.Check NEUE's competition here

Cynosure, Inc. (NASDAQ: CYNO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYNO stands at 0. In comparison, SNWV has a market cap of 50.6M. Regarding current trading prices, CYNO is priced at $66.00 on the NASDAQ, while SNWV trades at $5.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYNO currently has a P/E ratio of 105.35, whereas SNWV's P/E ratio is 17.82. In terms of profitability, CYNO's ROE is +0.03%, compared to SNWV's ROE of +17.28%. Regarding short-term risk, CYNO is less volatile compared to SNWV. This indicates lower risk in terms of short-term price fluctuations for CYNO.Check SNWV's competition here

Cynosure, Inc. (NASDAQ: CYNO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYNO stands at 0. In comparison, EKSO has a market cap of 38.6M. Regarding current trading prices, CYNO is priced at $66.00 on the NASDAQ, while EKSO trades at $15.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYNO currently has a P/E ratio of 105.35, whereas EKSO's P/E ratio is -3.11. In terms of profitability, CYNO's ROE is +0.03%, compared to EKSO's ROE of -1.77%. Regarding short-term risk, CYNO is less volatile compared to EKSO. This indicates lower risk in terms of short-term price fluctuations for CYNO.Check EKSO's competition here

Cynosure, Inc. (NASDAQ: CYNO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYNO stands at 0. In comparison, BEAT has a market cap of 29.1M. Regarding current trading prices, CYNO is priced at $66.00 on the NASDAQ, while BEAT trades at $0.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYNO currently has a P/E ratio of 105.35, whereas BEAT's P/E ratio is -0.94. In terms of profitability, CYNO's ROE is +0.03%, compared to BEAT's ROE of -10.34%. Regarding short-term risk, CYNO is less volatile compared to BEAT. This indicates lower risk in terms of short-term price fluctuations for CYNO.Check BEAT's competition here

Cynosure, Inc. (NASDAQ: CYNO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYNO stands at 0. In comparison, STSSW has a market cap of 839.4K. Regarding current trading prices, CYNO is priced at $66.00 on the NASDAQ, while STSSW trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYNO currently has a P/E ratio of 105.35, whereas STSSW's P/E ratio is -0.03. In terms of profitability, CYNO's ROE is +0.03%, compared to STSSW's ROE of N/A. Regarding short-term risk, CYNO is more volatile compared to STSSW. This indicates higher risk in terms of short-term price fluctuations for CYNO.Check STSSW's competition here

Cynosure, Inc. (NASDAQ: CYNO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYNO stands at 0. In comparison, ABCO has a market cap of 0. Regarding current trading prices, CYNO is priced at $66.00 on the NASDAQ, while ABCO trades at $0.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYNO currently has a P/E ratio of 105.35, whereas ABCO's P/E ratio is 0.52. In terms of profitability, CYNO's ROE is +0.03%, compared to ABCO's ROE of +0.19%. Regarding short-term risk, CYNO is less volatile compared to ABCO. This indicates lower risk in terms of short-term price fluctuations for CYNO.Check ABCO's competition here

Cynosure, Inc. (NASDAQ: CYNO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYNO stands at 0. In comparison, SCAI has a market cap of 0. Regarding current trading prices, CYNO is priced at $66.00 on the NASDAQ, while SCAI trades at $55.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYNO currently has a P/E ratio of 105.35, whereas SCAI's P/E ratio is 63.45. In terms of profitability, CYNO's ROE is +0.03%, compared to SCAI's ROE of +0.09%. Regarding short-term risk, CYNO is less volatile compared to SCAI. This indicates lower risk in terms of short-term price fluctuations for CYNO.Check SCAI's competition here

Cynosure, Inc. (NASDAQ: CYNO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYNO stands at 0. In comparison, LDR has a market cap of 0. Regarding current trading prices, CYNO is priced at $66.00 on the NASDAQ, while LDR trades at $67.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYNO currently has a P/E ratio of 105.35, whereas LDR's P/E ratio is N/A. In terms of profitability, CYNO's ROE is +0.03%, compared to LDR's ROE of +1.17%. Regarding short-term risk, CYNO is similarly volatile compared to LDR. This indicates similar risk in terms of short-term price fluctuations for CYNO.Check LDR's competition here

Cynosure, Inc. (NASDAQ: CYNO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYNO stands at 0. In comparison, MZOR has a market cap of 0. Regarding current trading prices, CYNO is priced at $66.00 on the NASDAQ, while MZOR trades at $58.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYNO currently has a P/E ratio of 105.35, whereas MZOR's P/E ratio is -70.18. In terms of profitability, CYNO's ROE is +0.03%, compared to MZOR's ROE of -0.14%. Regarding short-term risk, CYNO is more volatile compared to MZOR. This indicates higher risk in terms of short-term price fluctuations for CYNO.Check MZOR's competition here

Cynosure, Inc. (NASDAQ: CYNO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYNO stands at 0. In comparison, MEDC has a market cap of 0. Regarding current trading prices, CYNO is priced at $66.00 on the NASDAQ, while MEDC trades at $0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYNO currently has a P/E ratio of 105.35, whereas MEDC's P/E ratio is N/A. In terms of profitability, CYNO's ROE is +0.03%, compared to MEDC's ROE of N/A. Regarding short-term risk, CYNO is less volatile compared to MEDC. This indicates lower risk in terms of short-term price fluctuations for CYNO.Check MEDC's competition here

Cynosure, Inc. (NASDAQ: CYNO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYNO stands at 0. In comparison, STJ has a market cap of 0. Regarding current trading prices, CYNO is priced at $66.00 on the NASDAQ, while STJ trades at $80.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYNO currently has a P/E ratio of 105.35, whereas STJ's P/E ratio is 34.69. In terms of profitability, CYNO's ROE is +0.03%, compared to STJ's ROE of +0.21%. Regarding short-term risk, CYNO is less volatile compared to STJ. This indicates lower risk in terms of short-term price fluctuations for CYNO.Check STJ's competition here

Cynosure, Inc. (NASDAQ: CYNO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYNO stands at 0. In comparison, LPNT has a market cap of 0. Regarding current trading prices, CYNO is priced at $66.00 on the NASDAQ, while LPNT trades at $64.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYNO currently has a P/E ratio of 105.35, whereas LPNT's P/E ratio is 67.44. In terms of profitability, CYNO's ROE is +0.03%, compared to LPNT's ROE of +0.05%. Regarding short-term risk, CYNO is more volatile compared to LPNT. This indicates higher risk in terms of short-term price fluctuations for CYNO.Check LPNT's competition here

Cynosure, Inc. (NASDAQ: CYNO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYNO stands at 0. In comparison, PMC has a market cap of 0. Regarding current trading prices, CYNO is priced at $66.00 on the NASDAQ, while PMC trades at $29.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYNO currently has a P/E ratio of 105.35, whereas PMC's P/E ratio is 47.95. In terms of profitability, CYNO's ROE is +0.03%, compared to PMC's ROE of +0.04%. Regarding short-term risk, CYNO is less volatile compared to PMC. This indicates lower risk in terms of short-term price fluctuations for CYNO.Check PMC's competition here

Cynosure, Inc. (NASDAQ: CYNO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYNO stands at 0. In comparison, ABAX has a market cap of 0. Regarding current trading prices, CYNO is priced at $66.00 on the NASDAQ, while ABAX trades at $83.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYNO currently has a P/E ratio of 105.35, whereas ABAX's P/E ratio is 70.62. In terms of profitability, CYNO's ROE is +0.03%, compared to ABAX's ROE of +0.10%. Regarding short-term risk, CYNO is more volatile compared to ABAX. This indicates higher risk in terms of short-term price fluctuations for CYNO.Check ABAX's competition here

Cynosure, Inc. (NASDAQ: CYNO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYNO stands at 0. In comparison, EVHC has a market cap of 0. Regarding current trading prices, CYNO is priced at $66.00 on the NASDAQ, while EVHC trades at $45.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYNO currently has a P/E ratio of 105.35, whereas EVHC's P/E ratio is -3.20. In terms of profitability, CYNO's ROE is +0.03%, compared to EVHC's ROE of +0.07%. Regarding short-term risk, CYNO is more volatile compared to EVHC. This indicates higher risk in terms of short-term price fluctuations for CYNO.Check EVHC's competition here

Cynosure, Inc. (NASDAQ: CYNO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYNO stands at 0. In comparison, COTV has a market cap of 0. Regarding current trading prices, CYNO is priced at $66.00 on the NASDAQ, while COTV trades at $44.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYNO currently has a P/E ratio of 105.35, whereas COTV's P/E ratio is 26.51. In terms of profitability, CYNO's ROE is +0.03%, compared to COTV's ROE of +0.14%. Regarding short-term risk, CYNO is more volatile compared to COTV. This indicates higher risk in terms of short-term price fluctuations for CYNO.Check COTV's competition here

Cynosure, Inc. (NASDAQ: CYNO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYNO stands at 0. In comparison, AMSG has a market cap of 0. Regarding current trading prices, CYNO is priced at $66.00 on the NASDAQ, while AMSG trades at $67.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYNO currently has a P/E ratio of 105.35, whereas AMSG's P/E ratio is N/A. In terms of profitability, CYNO's ROE is +0.03%, compared to AMSG's ROE of +0.08%. Regarding short-term risk, CYNO is less volatile compared to AMSG. This indicates lower risk in terms of short-term price fluctuations for CYNO.Check AMSG's competition here

Cynosure, Inc. (NASDAQ: CYNO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYNO stands at 0. In comparison, SPNC has a market cap of 0. Regarding current trading prices, CYNO is priced at $66.00 on the NASDAQ, while SPNC trades at $38.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYNO currently has a P/E ratio of 105.35, whereas SPNC's P/E ratio is -24.03. In terms of profitability, CYNO's ROE is +0.03%, compared to SPNC's ROE of -0.61%. Regarding short-term risk, CYNO is more volatile compared to SPNC. This indicates higher risk in terms of short-term price fluctuations for CYNO.Check SPNC's competition here

Cynosure, Inc. (NASDAQ: CYNO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYNO stands at 0. In comparison, DSCI has a market cap of 0. Regarding current trading prices, CYNO is priced at $66.00 on the NASDAQ, while DSCI trades at $7.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYNO currently has a P/E ratio of 105.35, whereas DSCI's P/E ratio is -0.02. In terms of profitability, CYNO's ROE is +0.03%, compared to DSCI's ROE of -0.00%. Regarding short-term risk, CYNO is less volatile compared to DSCI. This indicates lower risk in terms of short-term price fluctuations for CYNO.Check DSCI's competition here

Cynosure, Inc. (NASDAQ: CYNO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYNO stands at 0. In comparison, SPAN has a market cap of 0. Regarding current trading prices, CYNO is priced at $66.00 on the NASDAQ, while SPAN trades at $29.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYNO currently has a P/E ratio of 105.35, whereas SPAN's P/E ratio is N/A. In terms of profitability, CYNO's ROE is +0.03%, compared to SPAN's ROE of +0.17%. Regarding short-term risk, CYNO is less volatile compared to SPAN. This indicates lower risk in terms of short-term price fluctuations for CYNO.Check SPAN's competition here

Cynosure, Inc. (NASDAQ: CYNO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYNO stands at 0. In comparison, EXAC has a market cap of 0. Regarding current trading prices, CYNO is priced at $66.00 on the NASDAQ, while EXAC trades at $49.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYNO currently has a P/E ratio of 105.35, whereas EXAC's P/E ratio is 3510.33. In terms of profitability, CYNO's ROE is +0.03%, compared to EXAC's ROE of +0.00%. Regarding short-term risk, CYNO is more volatile compared to EXAC. This indicates higher risk in terms of short-term price fluctuations for CYNO.Check EXAC's competition here